Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $10.3M (cash outflow) rose 66.9% year over year, ahead of the +26.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Free cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +66.9% holds above the trailing-twelve-month pace of +26.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.3M+2.2% QoQ
Last fiscal yearDec 2025
-$29.65M-1.5% YoY
LTMMar 2026
-$32.14M+26.7% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.9%——
1 year-1.5%——
3-year CAGR+15.8%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

Mixed currencies · from the cash flow

Latest · FY2025
(29.65M) USD
Year-over-year change
+1.5%

Free Cash Flow vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.7% is the 2nd highest of 8, against a peer median of -31.1%.
  • Over three fiscal years its annual growth of +15.8% compares with a peer median of -6.7%.
EPRX.TO Competitors
Free Cash Flow for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$77.34M CAD-56.3%-50.3%24.9%
DR.TOMedical Facilities CorporationLTM Mar 2026$43.17M USD-36.9%-6.6%14.1%
PRN.TOProfound Medical Corp.LTM Mar 2026$38.5M USD+44.5%+14.8%205.2%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$32.14M USD+26.7%+15.8%—
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$20.2M CAD-24.5%—7.4%
TSND.TOTerrAscend Corp.LTM Mar 2026$15.17M USD-31.1%—5.8%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.86M USD-52.0%-6.7%15.4%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$3.21M CAD-18.5%-16.2%—
Peer median (excluding EPRX.TO) —-31.1%-6.7%14.8%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(23.37M)(23.26M)(28.15M)(25.74M)(38.61M)
Depreciation & Amortization111.53K200.24K117.1K235.25K241.88K
Deferred Income Tax1.2M0000
Stock-Based Compensation4.21M1.43M1.06M3.22M9.04M
Change in Working Capital(211.43K)2.07M4.76M(6.76M)(726.19K)
Accounts Receivables190.89K310.06K(105.39K)(101.39K)(439K)
Inventory0(1.32M)(435.12K)00
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(402.32K)1.76M4.87M(5.95M)(2.69M)
Other Non-Cash Items3.41M776.17K1.51M(944.03K)1M
Operating Cash Flow(14.64M)(18.78M)(21.02M)(29.99M)(29.05M)
Capital Expenditures(431.67K)(308.37K)(55.25K)(104.23K)(599.26K)
Acquisitions (Net)0310039.82K0
Purchases of Investments(9M)(310)000
Sales of Investments09.01M000
Other Investing Activities(5.02M)310027.81K0
Investing Cash Flow(14.45M)8.7M(73.2K)(75.16K)(599.26K)
Debt Repayment12.17M(97.49K)(108.75K)(9.14M)0
Common Stock Issued29.67M10.64M11.96M54.56M77.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(87.7K)(87.7K)9.11M363.06K0
Financing Cash Flow49.92M13.52M20.96M45.78M77.39M
Effect of Forex Changes(81.63K)396.83K821.4K(1.96M)(1.99M)
Net Change in Cash20.74M3.84M1.08M13.76M45.75M
Free Cash Flow(15.07M)(19.08M)(21.09M)(30.1M)(29.65M)

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.